Health & Fitness
Health and Fitness
Health and Fitness
Wed, June 2, 2010
Tue, June 1, 2010 BrainStorm To Present at Inaugural Stem Cell Conference Hosted by National Securities Corporation and MD Becker Partners
NEW YORK & PETACH TIKVAH, Israel--([ BUSINESS WIRE ])--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics today announced that Rasheda Ali, a member of BrainStorma™s advisory board and Professor Eldad Melamed, BrainStorma™s Chief Medical Advisor, will be presenting at today's Inaugural Stem Cell Investor and Executive Networking Conference Event from 11:00 a.m. to 4:00 p.m. (EDT), at National Securities Corporation Global Headquarters at 120 Broadway, (2nd Floor Conference Center) in New York City.
At the conference, Rasheda Ali, the revered author and daughter of renowned boxer Muhammad Ali, will provide remarks at 11:00 AM and discuss BrainStorm and its upcoming ALS clinical trials.
Professor Eldad Melamed, the former Head of Neurology, Rabin Medical Center, and Tel-Aviv University, and a member of the Scientific Committee of the Michael J. Fox Foundation for Parkinson's Research, will panel a session titled aAutologous Approachesa at 2:00 PM discussing BrainStorma™s approach to treating ALS patients.
The Stem Cell Investor & Executive Networking Conference Event, hosted by National Securities Corporation and MD Becker Partners, is strategically designed to unite investors with industry executives to exchange information and highlight opportunities in the expanding stem cell universe. The event will bring together the founding visionary researchers, clinicians, entrepreneurs, key investors, and other stakeholders to offer compelling panel discussions, share information, and discuss the future of the field. For more information on the conference please go to [ http://www.mdbpartners.com/science ].
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Prof. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's current focus is on ALS, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at [ http://www.sec.gov ]. The Company does not undertake any obligation to update forward-looking statements made by us.
